The Influence of Free Hemoglobin and Bilirubin on Heparin Monitoring by Activated Partial Thromboplastin Time and Anti-Xa Assay

被引:58
|
作者
Kostousov, Vadim [1 ,3 ]
Nguyen, Kim [3 ]
Hundalani, Shilpa G. [2 ,4 ]
Teruya, Jun [1 ,2 ,3 ]
机构
[1] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Texas Childrens Hosp, Div Transfus Med & Coagulat, Houston, TX 77030 USA
[4] Texas Childrens Hosp, Dept Pediat, Sect Neonatol, Houston, TX 77030 USA
关键词
EXTRACORPOREAL MEMBRANE-OXYGENATION; COAGULATION MANAGEMENT; CENTRIFUGAL PUMPS; HEMOLYSIS; ANTICOAGULATION; INTERFERENCE;
D O I
10.5858/arpa.2013-0572-OA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Elevated free hemoglobin (Hb) and bilirubinemia complicate extracorporeal membrane oxygenation and could affect unfractionated heparin (UH) therapy monitoring by anti-Xa assay and activated partial thromboplastin time (aPTT). Objectives.-To compare in vitro response of anti-Xa and aPTT assays to UH in samples with artificial hyperbilirubinemia and hyperhemoglobinemia and to estimate if this interference is also observed in vivo in pediatric extracorporeal membrane oxygenation. Design.-Measurement of aPTT and anti-Xa activity in plasma spiked with UH and increased concentration of free Hb and/or conjugated bilirubin. All samples with antiXa activity, antithrombin, free Hb, and bilirubin determination and infused dose of UH from inpatients on extracorporeal membrane oxygenation were extracted from the clinical patient database and analyzed. Results.-Each increment of free Hb by 100 mg/dL significantly shortened aPTT, whereas an increment of bilirubin by 6 mg/dL caused significant prolongation of aPTT and stepwise increase of free Hb and/or bilirubin in plasma decreased anti-Xa activity by 0.03 to 0.05 IU/mL. Extracorporeal membrane oxygenation samples with free Hb 50 mg/dL or greater had significantly lower anti-Xa activity compared with normal ones: 0.33 (0.25-0.42) versus 0.4 (0.31-0.48) IU/mL (P = .01), despite the identical UH infusion and similar antithrombin activity. Moderate increase of free Hb by 59 mg/dL was associated with absolute decrease of anti-Xa activity by 0.07 IU/mL. Conclusions.-Activated partial thromboplastin time and anti-Xa assay are affected by elevated level of free Hb and/or bilirubin in the presence of UH, and lower antiXa activity is noted in extracorporeal membrane oxygenation patients with elevated free Hb. Severe hemolysis and/or hyperbilirubinemia could compromise UH monitoring based on these assays.
引用
收藏
页码:1503 / 1506
页数:4
相关论文
共 50 条
  • [41] Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial
    Aubron, Cecile
    Chapalain, Xavier
    Bailey, Michael
    Board, Jasmin
    Buhr, Heidi
    Cartwright, Bruce
    Dennis, Mark
    Hodgson, Carol
    Forrest, Paul
    Mcilroy, David
    Murphy, Deirdre
    Murray, Lynne
    Pellegrino, Vincent
    Pilcher, David
    Sheldrake, Jayne
    Tran, Huyen
    Vallance, Shirley
    Cooper, D. James
    Mcquilten, Zoe
    CRITICAL CARE EXPLORATIONS, 2023, 5 (11) : E0999
  • [42] Early Anti-Xa Assay-Guided Low Molecular Weight Heparin Chemoprophylaxis Is Safe in Adult Patients with Acute Traumatic Brain Injury
    Rodier, Simon G.
    Kim, Mirhee
    Moore, Samantha
    Frangos, Spiros G.
    Tandon, Manish
    Klein, Michael J.
    Berry, Cherisse D.
    Huang, Paul P.
    Dimaggio, Charles J.
    Bukur, Marko
    AMERICAN SURGEON, 2020, 86 (04) : 369 - 376
  • [43] Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients
    Mirjam Bachler
    Christian Niederwanger
    Tobias Hell
    Judith Höfer
    Dominic Gerstmeyr
    Bettina Schenk
    Benedikt Treml
    Dietmar Fries
    Journal of Thrombosis and Thrombolysis, 2019, 48 : 466 - 474
  • [44] Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients
    Bachler, Mirjam
    Niederwanger, Christian
    Hell, Tobias
    Hoefer, Judith
    Gerstmeyr, Dominic
    Schenk, Bettina
    Treml, Benedikt
    Fries, Dietmar
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 48 (03) : 466 - 474
  • [45] Use of Low-Molecular-Weight Heparin and Peak anti-Xa Monitoring In Severe SARS-CoV-2 Disease: A Brief Report
    Toor, Rebecca
    Zamora, Francis J.
    Fatteh, Naaz
    Drexler, Nathan
    Lozada, Jose
    HOSPITAL PHARMACY, 2021, 56 (06) : 640 - 645
  • [46] Monitoring Direct Thrombin Inhibitors With Calibrated Diluted Thrombin Time vs Activated Partial Thromboplastin Time in Pediatric Patients
    Hasan, Rida A.
    Pak, Jennifer
    Kirk, Christa Jefferis
    Friedland-Little, Joshua M.
    Chandler, Wayne L.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 159 (01) : 60 - 68
  • [47] Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation: Is Anti-Factor Xa Assay (Heparin Level) a Better Test?
    Trung Nguyen
    Musick, Matthew
    Teruya, Jun
    PEDIATRIC CRITICAL CARE MEDICINE, 2014, 15 (02) : 178 - 179
  • [48] An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation
    Teng, Yuan
    Yan, Shujie
    Liu, Gang
    Lou, Song
    Zhang, Yang
    Ji, Bingyang
    FRONTIERS IN MEDICINE, 2022, 9
  • [49] Time to Target Anti-Xa Level in Obese Vs Nonobese Patients Using an Adjusted Body Weight Heparin Infusion Protocol for the Treatment of Venous Thromboembolism
    Eibye, Mary K.
    Poston, Jacqueline N.
    Kennedy, Amanda G.
    Desarno, Michael
    Nashett, Rebecca M.
    ANNALS OF PHARMACOTHERAPY, 2025,
  • [50] Effect of Body Mass Index on Bleeding Frequency and Activated Partial Thromboplastin Time in Weight-Based Dosing of Unfractionated Heparin: A Retrospective Cohort Study
    Bauer, Seth R.
    Ou, Narith N.
    Dreesman, Benjamin J.
    Armon, Jeffrey J.
    Anderson, Jan A.
    Cha, Stephen S.
    Oyen, Lance J.
    MAYO CLINIC PROCEEDINGS, 2009, 84 (12) : 1073 - 1078